한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

the history of sirnax pharmaceuticals, a company focused on drug discovery and treatment of new diseases, has been full of ups and downs. from early progress to the recent funding crisis, the future of sirnax pharmaceuticals is full of uncertainty. although the company released its annual report in 2023 and actively sought new partnership opportunities, they are currently in trouble.

portfolio and surveys

sirnaomics' investment portfolio has always been an important part of the company, especially its investment in sirnaomics in hong kong. however, these investments have potential risks, causing the company to face financial difficulties. the company is actively investigating and trying to understand the status of the investment portfolio and take appropriate measures. at present, the company has hired lawyers and accounting consultants to conduct an independent investigation and expects to release a report in september 2024.

seeking cooperation and finding new paths

sirno pharmaceuticals is facing a funding crisis and must seek new financing options. although the company has made some progress, such as the cooperation agreement with hualan biotechnology, these cannot completely solve the problems the company is currently facing. in order to obtain funds and get out of the predicament, sirno pharmaceuticals is actively seeking cooperation opportunities and negotiating and communicating with other industry players.

potential collaboration opportunities

sirnax is exploring various collaboration models, including co-development, in-licensing and out-licensing arrangements, which are designed to improve the company's efficiency in r&d and commercialization and bring new opportunities for its products.

challenges and the future

the current predicament of sirna pharmaceuticals may lead to a significant decline in its market value. although the company still has the possibility of negotiation and cooperation, it remains to be seen whether it can find a suitable cooperation opportunity in the end. at the same time, the company also needs to continue to work hard, actively respond to challenges and find new development directions.